



**Oregon Prescription Drug Affordability Board Regular Meeting**  
**Wednesday, September 16, 2026**  
**Minutes approved by the board Oct. 21, 2026**

**Web link to the meeting video:** <https://youtu.be/Ka0ND0neLdU>

**Web link to the meeting materials:** <https://dfr.oregon.gov/pdab/Documents/20260916-PDAB-document-package.pdf>

**Call to order:** Chair Shelley Bailey called the meeting to order at 8 a.m.

**Roll call:**

Present: Chair Shelley Bailey, Vice Chair Dan Hartung, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Noelle Redmond

Absent: Lauri Hoagland

The board chair announced a change in the agenda order. The board discussed policy recommendations before the 2026 drug review.

**Board declarations of conflict of interest and meetings with entities or individuals related to board activities:** John Murray and Chris Laman provided statements. View the video here: [00:01:31](#).

**PDAB program update:** Sarah Young, PDAB executive director, provided a program update. View the video here: [00:02:57](#).

**Approval of board minutes:** Chair Bailey approved by consensus the Aug. 19, 2026, minutes as shown on [Pages 2-3](#) of the agenda materials. View the video here: [00:07:32](#).

**General public comment:** Public comment was received from the following individuals who signed up in advance: Mary Anne Cooper, Regence BlueCross BlueShield of Oregon; Tiffany Westrich-Robertson, EACH/PIC Coalition; Lorren Sandt, Caring Ambassadors Program; Dharia McGrew, PhRMA; Kelsey Wilson, PCMA; Derek Flowers, Value of Care Coalition; and LuGina Mendez Harper, Prime Therapeutics. The board received four general written comments, which are posted on the [PDAB website](#). View the video here: [00:08:01](#).

**Oregon Office of Rural Health presentation:** Robert Duehmig, director of the Oregon Office of Rural Health, presented on his office's mission and provided statistics about rural health in Oregon. View the slides on [Pages 4-26](#) of the agenda materials. View the video here: [00:30:11](#).

**Policy concepts for the annual report:** Cortnee Whitlock, PDAB program and senior policy analyst, led the board through a discussion about the policy concepts introduced at the July 15 board meeting. Vice Chair Dan Hartung also talked about a policy memo he submitted to the board about setting reference prices for state-regulated commercial markets using Medicare's



maximum fair price. Board members agreed to move forward on policy recommendations about the concepts presented at the July 15 meeting: commercial health plan continuity of care; expanding Oregon PDAB scope; orphan drug language refinement in the PDAB statute; and address key issues in pharmacy benefit manager practices. The board did not advance the proposal about setting reference prices. Read the [proposed policy memos](#) posted on the PDAB website. View the video here: [01:10:56](#).

**Drug review public comment:** Five people spoke during the drug review public comment period. See Table 1. The board received seven written comments about drugs under review. The drug review letters are posted on the [PDAB website](#). View the video here: [02:59:15](#).

*Table 1 Speakers during the drug review public comment period on Sept. 16, 2026*

| Speaker name  | Affiliation        | Drug     |
|---------------|--------------------|----------|
| Lorren Sandt  | Caring Ambassadors | Keytruda |
| Scott Devine  | Merck              | Keytruda |
| Chris Herbine | Johnson & Johnson  | Tremfya  |
| Lisa Carman   | Genentech          | Ocrevus  |
| Lisa Carman   | Genentech          | Xolair   |

**2026 Drug review discussion:** Cortnee Whitlock reviewed the 2026 drug review roadmap on [Page 27](#) of the agenda materials and presented the drug review reports from the web links on [Page 29](#). Board members discussed all the drugs on the 2026 review list and identified three for further discussion at the Oct. 21 board meeting: Keytruda, a treatment for cancer; and Skyrizi and Tremfya, treatments for inflammatory conditions. Find all the drug review documents on the [drug review page](#) of the PDAB website. View the video here: [02:58:54](#).

**Announcements:** Chair Bailey said the agenda item about the year-round feedback form will be tabled until the Oct. 21 meeting. She announced the next board meeting will be on Oct. 21, 2026, at 8 a.m. View the video here: [04:23:08](#).

**Adjournment:** Chair Bailey adjourned the meeting at 12:34 p.m. with all board members in agreement. View the video here: [04:23:1](#).